171 related articles for article (PubMed ID: 30489289)
1. Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor.
Fergadis E; Gavrielatou N; Skouteris N; Athanasopoulos A; Lianos E; Kosmas C
Anticancer Drugs; 2019 Feb; 30(2):205-208. PubMed ID: 30489289
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience.
Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N
Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation: report of a case.
Miltiadous C; Dimitriadis GK; Roditis P; Kosmas C
Anticancer Drugs; 2017 Feb; 28(2):237-241. PubMed ID: 27749622
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
Fergadis E; Assi A; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Dimitriadis GK; Grivas A; Athanasopoulos A; Lianos E; Kosmas C
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e50-e57. PubMed ID: 31884151
[TBL] [Abstract][Full Text] [Related]
6. Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation;
Kosmas C; Kranidioti E; Kosma A; Karakosta M; Miltiadous C; Grivas A; Athanasopoulos A; Lianos E
Leuk Lymphoma; 2019 Jul; 60(7):1819-1822. PubMed ID: 30618317
[No Abstract] [Full Text] [Related]
7. High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.
El-Helw LM; Naik JD; Chester JD; Joffe JK; Selby PJ; Coleman RE
BJU Int; 2006 Sep; 98(3):519-25. PubMed ID: 16925746
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience.
Yildiran Keskin GS; Erturk I; Aykan MB; Acar R; Dumludag A; Topal A; Koseoglu C; Kuzu OF; Ornek E; Karadurmus N
Oncol Res Treat; 2024; 47(6):262-272. PubMed ID: 38583428
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study.
Baek HJ; Park HJ; Sung KW; Lee SH; Han JW; Koh KN; Im HJ; Kang HJ; Park KD
J Neurooncol; 2013 Sep; 114(3):329-38. PubMed ID: 23824533
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
12. The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience.
Topal A; Erturk I; Koseoglu C; Dumludag A; Kuzu ÖF; Durmaz P; Akdag G; Keskin GSY; Karadurmus N
Clin Genitourin Cancer; 2024 Aug; 22(4):102106. PubMed ID: 38852437
[TBL] [Abstract][Full Text] [Related]
13. Control of relapsed germ cell tumor and SLE nephritis by high-dose chemotherapy and autologous hematopoietic cell transplantation.
Kosmas C; Papachrysanthou T; Daladimos T; Athanasopoulos A; Tsavaris N; Vlachoyiannopoulos PG
Future Oncol; 2013 Sep; 9(9):1401-6. PubMed ID: 23980687
[TBL] [Abstract][Full Text] [Related]
14. High-dose Chemotherapy With Autologous Stem Cell Rescue in Saudi Children Less Than 3 Years of Age With Embryonal Brain Tumors.
Alsultan A; Alharbi M; Al-Dandan S; Bayoumi Y; Alharbi T; Alsudairy R; Alomari A; Aljamaan K; Musleh O; Alharbi Q; Jarrar M
J Pediatr Hematol Oncol; 2015 Apr; 37(3):204-8. PubMed ID: 25551668
[TBL] [Abstract][Full Text] [Related]
15. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
16. Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC; Bracho F; Davenport V; Slack R; Areman E; Shen V; Lenarsky C; Weinthal J; Hughes R; Cairo MS
J Pediatr Hematol Oncol; 2001; 23(5):300-5. PubMed ID: 11464987
[TBL] [Abstract][Full Text] [Related]
17. Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era.
Hamid AA; Markt SC; Vicier C; McDermott K; Richardson P; Ho VT; Sweeney CJ
Clin Genitourin Cancer; 2019 Feb; 17(1):58-64.e1. PubMed ID: 30309761
[TBL] [Abstract][Full Text] [Related]
18. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.
Smardova L; Engert A; Haverkamp H; Raemakers J; Baars J; Pfistner B; Diehl V; Josting A
Leuk Lymphoma; 2005 Jul; 46(7):1017-22. PubMed ID: 16019552
[TBL] [Abstract][Full Text] [Related]
19. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
20. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
